Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

• US 10,239,911 B2
• Filed: 06/06/2018
• Issued: 03/26/2019
• Est. Priority Date: 03/06/2015
• Status: Active Grant

• Current Assignee: Atea Pharmaceuticals, Inc.
• Original Assignee: Atea Pharmaceuticals, Inc.
• Inventors: Sommadossi, Jean-Pierre, Moussa, Adel
• Primary Examiner(s): McIntosh, III, Traviss C
• Application Number:
  US16/001,549
• Publication Number:
  US 20180282364A1
• Time in Patent Office: 293 Days
• Field of Search: None
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07H 19/16 Purine radicals
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 19/207 the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Abstract

A compound of the structure:

or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Claims

1. A method for treating hepatitis C in a host in need thereof comprising administering an anti-HCV effective amount of a compound of the formula:

2. The method of claim 1, comprising an anti-HCV effective amount of a compound of the formula:

3. The method of claim 1, comprising an anti-HCV effective amount of a compound of the formula:

4. The method of claim 1, wherein the compound is administered orally.

5. The method of claim 4, wherein the compound is administered in a tablet or a capsule.

6. The method of claim 1, wherein the host is a human.

7. The method of claim 2, wherein the compound is administered orally.

8. The method of claim 7, wherein the compound is administered in a tablet or a capsule.

9. The method of claim 2, wherein the host is a human.

10. The method of claim 3, wherein the compound is administered orally.

11. The method of claim 10, wherein the compound is administered in a tablet or a capsule.

12. The method of claim 3, wherein the host is a human.

13. A method for treating hepatitis C in a host in need thereof comprising administering an anti-HCV effective amount of a compound of the formula:

14. The method of claim 13, comprising an anti-HCV effective amount of a compound of the formula:

15. The method of claim 13, comprising an anti-HCV effective amount of a compound of the formula:

16. The method of claim 13, wherein the compound is administered orally.

17. The method of claim 16, wherein the compound is administered in a tablet or a capsule.

18. The method of claim 13, wherein the host is a human.

19. The method of claim 14, wherein the compound is administered orally.

20. The method of claim 19, wherein the compound is administered in a tablet or a capsule.

21. The method of claim 14, wherein the host is a human.

22. The method of claim 15, wherein the compound is administered orally.

23. The method of claim 22, wherein the compound is administered in a tablet or a capsule.

24. The method of claim 15, wherein the host is a human.